Stocks and Investing
Stocks and Investing
Wed, February 28, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Serge Belanger Reiterated (VRDN) at Strong Buy and Held Target at $30 on, Feb 28th, 2024
Serge Belanger of Needham, Reiterated "Viridian Therapeutics, Inc." (VRDN) at Strong Buy and Held Target at $30 on, Feb 28th, 2024.
Serge has made no other calls on VRDN in the last 4 months.
There are 4 other peers that have a rating on VRDN. Out of the 4 peers that are also analyzing VRDN, 0 agree with Serge's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Serge
- Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $36 on, Tuesday, December 19th, 2023
- Douglas Tsao of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $37 on, Monday, December 18th, 2023
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $35 on, Thursday, December 14th, 2023
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $38 on, Tuesday, November 14th, 2023
Contributing Sources